The Impact of Pamidronate and Chemotherapy on Survival Times in Dogs with Appendicular Primary Bone Tumors Treated with Palliative Radiation Therapy

Oblak, Michelle L.; Boston, Sarah E.; Higginson, Geraldine; Patten, Steven G.; Monteith, Gabrielle; Woods, J. Paul

doi:10.1111/j.1532-950x.2012.00968.x

Cited by 32 publications

(43 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Average survival was 3.5 months with amputation alone and 10 months with amputation or radiation therapy and chemotherapy. These outcomes are numerically similar to previous reports of dogs treated for appendicular OSA . We conclude that treatment can extend survival, although a guarded long‐term prognosis must be given, and the role of chemotherapy remains unclear.…”

Section: Discussionsupporting

confidence: 86%

“…Survival differences between groups were not statistically significant, but this could relate to data limitations rather than to true lack of association. Our results are numerically comparable to prior studies that reported median OS of 1‐2 months with analgesics and 2‐5 months with amputation or radiation therapy . However, published studies of OSA treated with amputation and carboplatin or doxorubicin chemotherapy report longer median OS (range 8.6‐16.0 months) versus the 7 months observed in this group of dogs with tOSA .…”

Section: Discussionsupporting

confidence: 84%

“…Although treatment and follow‐up of individual cases varied widely, several findings are clinically relevant. First, dogs with appendicular HSA can respond favorably to treatment and achieve survival times numerically similar to reports of osteogenic OSA . Second, dogs with tOSA treated with amputation and chemotherapy survived a median of 7 months, which is numerically shorter than reported for other OSA variants and could suggest a more guarded prognosis for this subtype.…”

Section: Discussionsupporting

confidence: 63%

See 2 more Smart Citations

Primary appendicular hemangiosarcoma and telangiectatic osteosarcoma in 70 dogs: AVeterinarySociety ofSurgicalOncology retrospective study

Giuffrida

Kamstock²,

Selmic

et al. 2018

Veterinary Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionsupporting

confidence: 84%

Section: Discussionsupporting

confidence: 63%

See 1 more Smart Citation

Primary appendicular hemangiosarcoma and telangiectatic osteosarcoma in 70 dogs: AVeterinarySociety ofSurgicalOncology retrospective study

Giuffrida

Kamstock²,

Selmic

et al. 2018

Veterinary Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

“…Curative‐intent radiation is delivered as stereotactic radiation therapy (SRT) for OSA . Compared with SRT, palliative radiation therapy delivers a lower total dose or the total dose is delivered less intensively (weekly vs daily) . It is unknown if a palliative protocol can control tumour growth.…”

Section: Discussionmentioning

confidence: 99%

Limb‐sparing in dogs using patient‐specific, three‐dimensional‐printed endoprosthesis for distal radial osteosarcoma: A pilot study

Séguin¹,

Pinard²,

Lussier

et al. 2019

Vet Comparative Oncology

View full text Add to dashboard Cite

Limb‐sparing for distal radial osteosarcoma has a high rate of complications. Using personalized three‐dimensional (3D)‐printed implants might improve outcome. The goals of this study were to optimize use of patient‐specific, 3D‐printed endoprostheses for limb‐sparing in dogs in the clinical environment and to report the outcome. This was a pilot study where five client‐owned dogs were enrolled. Computed tomography (CT) of the thoracic limbs was performed, which was used to create patient‐specific endoprostheses and cutting guides, and repeated on the day of surgery. Intra‐arterial (IA) carboplatin was introduced in the clinical management. Limb‐sparing was performed. Outcome measures were time required to produce the endoprosthesis and cutting guide, fit between cutting guide and endoprosthesis with host bones, gait analysis, size of the tumour, percent tumour necrosis, complications, disease‐free interval (DFI) and survival time (ST). Four dogs received IA carboplatin. Excessive tumour growth between planning CT and surgery did not occur in any dog. The interval between the CT and surgery ranged from 14 to 70 days. Fit between the cutting‐guide and endoprosthesis with the host bones was good to excellent. At least one complication occurred in all dogs. Two dogs were euthanized with STs of 192 and 531 days. The other dogs were alive with a follow up of 534 to 575 days. IA chemotherapy is a promising strategy to minimize the risk of excessive tumour growth while waiting for the endoprosthesis and cutting‐guide to be made. The design of the cutting‐guide was critical for best fit of the endoprosthesis with host bones.

show abstract

“…In dogs, monthly parenteral administration of pamidronate or zoledronate is modestly effective in palliating bone cancer pain for osteosarcoma and other bone tumors [13–15] but does not appear to improve survival [16, 17]. Clinical bisphosphonate use in cats has been limited to case reports of non-cancer-related hypercalcemia and ossifying myositis [18–20].…”

Section: Introductionmentioning

confidence: 99%

Pamidronate Disodium for Palliative Therapy of Feline Bone-Invasive Tumors

Wypij

Heller²

2014

Veterinary Medicine International

View full text Add to dashboard Cite

This study sought to quantify in vitro antiproliferative effects of pamidronate in feline cancer cells and assess feasibility of use of pamidronate in cats by assessing short-term toxicity and dosing schedule in cats with bone-invasive cancer. A retrospective pilot study included eight cats with bone invasive cancer treated with intravenous pamidronate. In vitro, pamidronate reduced proliferation in feline cancer cells (P < 0.05). One cat treated with pamidronate in combination with chemotherapy and two cats treated with pamidronate as a single agent after failing prior therapy had subjective clinically stable disease; median progression free interval in these cats from initial pamidronate treatment was 81 days. Three cats developed azotemia while undergoing various treatment modalities including nonsteroidal anti-inflammatory drugs and pamidronate. Median overall survival was 116.5 days for all cats and 170 days for cats with oral squamous cell carcinoma. Median progression free survival was 55 days for all cats and 71 days for cats with oral squamous cell carcinoma. Pamidronate therapy appears feasible for administration in cancer bearing cats with aggressive bone lesions in the dose range of 1-2 mg/kg every 21–28 days for multiple treatments. No acute or short-term toxicity was directly attributable to pamidronate.

show abstract

The Impact of Pamidronate and Chemotherapy on Survival Times in Dogs with Appendicular Primary Bone Tumors Treated with Palliative Radiation Therapy

Abstract: Chemotherapy should be recommended in addition to a palliative RT protocol to improve survival of dogs with primary appendicular bone tumors. When combined with RT ± chemotherapy, pamidronate decreased MST and should not be included in a standard protocol.

Cited by 32 publications

References 28 publications

Primary appendicular hemangiosarcoma and telangiectatic osteosarcoma in 70 dogs: AVeterinarySociety ofSurgicalOncology retrospective study

Primary appendicular hemangiosarcoma and telangiectatic osteosarcoma in 70 dogs: AVeterinarySociety ofSurgicalOncology retrospective study

Limb‐sparing in dogs using patient‐specific, three‐dimensional‐printed endoprosthesis for distal radial osteosarcoma: A pilot study

Pamidronate Disodium for Palliative Therapy of Feline Bone-Invasive Tumors

Contact Info

Product

Resources

About